Editas Medicine (EDIT) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Editas Medicine (EDIT) has outperformed Valneva (VALN) over the past year, losing 31.6% versus a loss of 48.4%. Over five years, VALN leads with a -79.7% price change compared with -92.5% for EDIT. Valneva is the larger company by market cap ($539.5 million vs $436.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | VALN |
|---|---|---|
| Share price | $2.84 | $5.69 |
| Market cap | $436.17M | $539.55M |
| 1-day change | +3.27% | -3.07% |
| YTD return | +38.54% | -35.49% |
| 1-year return | -31.57% | -48.41% |
| 5-year return | -92.53% | -79.71% |
| Forward P/E | — | 4.78 |
| EPS (TTM) | $-0.68 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $12.18 |
| 52-week low | $1.66 | $4.75 |
| Distance from 52-week high | -34.41% | -53.28% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +107.75% | +115.29% |
| Average volume | 2.51M | 78.17K |
| Shares outstanding | 153.58M | 94.82M |
| Employees | 87 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed VALN by 16.8 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
EDIT vs VALN FAQ
Which is bigger, Editas Medicine or Valneva?
Valneva (VALN) is larger, with a market capitalization of $539.55M compared with $436.17M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or VALN?
EDIT returned -31.57% over the past 12 months, compared with -48.41% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.